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diagnosis and follow-up of cancers which could be used for selection of optimum therapeutic strategies would clearly be desirable.
In malignant breast tumours, CEA has been the only marker so far to partly satisfy the oncologists' requirements: pre-and postoperative elevations of CEA carry a poor prognosis (Wang et al., 1975) , while a subsquent rise in CEA is suggestive of metastasis (Tormey et al., 1975) . However, CEA is detectable in only one-third of cases when metastasis is discovered (39% in our experience), and in three-quarters of cases during the later course of disease (Namer et al., 1985) .
Recently, monoclonal antibodies have been generated against a new tumour marker, CA 15:3, a high molecular weight (290 Kd) carbohydrate.
In an initial study, the reliability of this marker was evaluated in a normal population and in patients with breast carcinoma at various stages. To assess the prognostic value of assays of this marker, tests were then conducted on a group of patients with metastatic breast cancer whose CEA level was negative when metastasis was diagnosed.
Patients and methods CA 15:3 The commercial CA 15:3 radioimmunometric assay (Oris Industrie S.A.) utilizes 2 monoclonal antibodies: MAB 115 D 8, directed against antigens of human milk fat globule membranes (Hilkens et al., 1983) and MAB DF 3, directed against a membrane fraction of human breast cancer (Kufe et al., 1984) . CA 15:3 is measured by a solid phase immunoradiometric system (ELSA tubes). The 115 D 8 antibody is coated on the ELSA solid phase; the DF 3 antibody, used as a tracer, is radiolabelled with iodine 125. The average CA 15:3 level in normal adults (except in pregnancy) is 13.7+5.2Uml-1 (mean+s.d.). The sensitivity of the method is 0.2 U ml -1. The threshold value was arbitrarily set at 12.5Uml-1 (no extrapolation on the calibration curve between 0 and 12.5). Intra-assay reproducibilities and dilution tests were between 4.8 and 13.2%. Inter-assay reproducibilities and dilution tests were between 12.9 and 14.5%. 
Results

Preliminary study
Only one of the 100 controls (patients without any malignant pathology) had a CA 15:3 level > 25Uml-.
The 85 breast cancer patients without nodal involvement and without metastasis were classified according to tumour size. In this population, the incidence of CA 15:3 levels >25Uml-1 was 9% (3/32) for TI, 18% (7/38) for T2, and 27% (4/15) for T3+T4N-. The overall incidence of CA 15:3 values >25U ml-1 in the 85 breast cancer patients without nodal involvement was 14/85 (16%). By contrast, 54% (21/39) of patients with nodal involvement presented with CA 15:3 levels >25Uml-'. (1987) , 55, [567] [568] [569] The Macmillan Press Ltd., 1987 .:. :.:
In view of these results, a larger population of patients with metastatic breast cancers was investigated, and CEA levels were compared with CA 15:3 concentrations.
Comparative study In order to compare CA 15:3 with CEA, 152 patients were studied at the time their first metastasis was discovered.
Seventy-nine of 82 patients with CEA levels between 10 and 500ngml-1 (96%) had a CA 15:3 level >25Uml-P (upper limit 18,000Uml-1). There was no correlation (r=0.032) between CA 15:3 and CEA levels. (Figure 2 Predictive value Nine of 48 patients with a CA 15:3 level >25Uml-' and a CEA level <5ngml-P, at the time that their first metastasis was detected, had had an assay performed over 6 months previously: 6 were >25Uml-1, even though there were no clinical signs of metastasis.
Discussion
Preliminary study CA 15:3 is a good tumour marker because only one control in 100 had an abnormal CA 15:3 level.
Various authors (Ballesta et al., 1985; Tobias et al., 1985) have set the significant threshold value between 30 and 50Uml-1 to avoid overestimation due to false positives. In breast cancer follow-up, the main problem is detection of local recurrence or distant metastasis; as false negatives must be avoided in these cases, we recommend a threshold value of 25Uml-1.
Analysis of CA 15:3 levels >25 U ml-1 according to tumour size revealed an increase in the prevalence of elevated values with increasing tumour size (Namer et al., 1985; Bolla et al., 1983) are comparable to those for CA 15:3. The incidence of CA 15:3 levels >25Uml-1 in the N-group was 16% and 54% in the N + group. The sensitivity is higher than the overall incidence of elevated CEA values (>5 ng ml-1) found during one of our previous studies: 7 positive CEA values in N -tumors versus Simultaneous measurement of CA 15:3 and CEA allowed monitoring of 128 (82 CEA-positive patients; 46 CA 15:3-positive and CEA-negative patients) out of 152 with breast cancer; 84% had at least one positive marker at diagnosis of metastasis.
Investigations concerning metastatic sites as a function of CA 15:3 levels gave findings similar to studies with CEA (Namer et al., 1978) . CA 15:3 levels in patients with multiple metastases were significantly higher than those in patients with a solitary metastasis. Other comparisons by metastatic site involved too few cases to allow any definite conclusions.
CEA, a marker commonly used for the follow-up of patients with breast cancer, allowed monitoring of two-thirds of patients (Namer et al., 1978) . The problem with CEA, however, is the fact that it is not often abnormal (only 39% of cases in our series). CA 15:3 was elevated in 66% of the population with a normal CEA level. For these patients, CA 15:3 allowed effective monitoring in two-thirds of cases; a greater frequency of elevated values means that information is available for a larger number of patients: this was the case for CA 15:3.
Furthermore, 6 of the 9 assays performed during the 6 months preceding the appearance of metastasis were >25 U ml-1 even though metastasis was not clinically evident. This suggests that repeat CA 15:3 measurements during the follow-up of patients with no evidence of disease allows metastasis to be predicted before clinical manifestations occur.
In conclusion, CA 15:3 is more sensitive than CEA when the primary tumour is diagnosed and when metastasis is discovered. In this last situation, it allowed monitoring in two-thirds of the cases. CA 15:3 levels were elevated more frequently than CEA levels, and CA 15:3 thus appears a superior marker than CEA in breast cancer prognosis.
